A Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy
Latest Information Update: 21 May 2024
At a glance
- Drugs EBT 101 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; First in man
- Sponsors Excision BioTherapeutics
- 14 May 2024 Planned End Date changed from 1 Mar 2025 to 1 May 2025.
- 14 May 2024 Planned primary completion date changed from 1 Dec 2024 to 1 May 2025.
- 14 May 2024 Status changed from recruiting to active, no longer recruiting.